课题基金 / 基金详情

项目摘要

项目成果

Frederic Barr的其他基金

相似基金

相关文献

中文摘要
翻译
该项目的直接目标是调查融合阳性和融合阴性横纹肌肉瘤(RMS)肿瘤之间DNA甲基化的差异。为了准备这项分析,编辑了Infinium HumanMethylation27 BeadChip数据库,删除了定位于X和Y染色体或重复区域的探针、含有多态位点的探针、具有不明确基因组位置的探针或没有可检测到信号的探针。对这个编辑的数据库应用非监督分析算法显示了两个不同的簇,一个包含融合阳性的RMS病例,另一个包含融合阴性的RMS病例。这种不同的甲基化进一步表现为与融合阴性肿瘤相比,融合阳性肿瘤中低甲基化位点的发生率增加。在两个RMS亚型之间存在差异甲基化的探针中,融合阳性亚群中的低甲基化位点比高甲基化位点多3倍。这种差异甲基化在定位到启动子区域和/或CpG岛的探针中尤为突出。由于最初的分析确定甲基化状态足以对RMS肿瘤的融合状态进行分类,我们接下来调查了这种分类所需的探针数量。寻找最少可区分CpG位点的训练算法确定,11个探针的甲基化状态足以区分融合阳性和融合阴性的RMS肿瘤。在这组11个探针中,与融合阴性病例相比,融合阳性的病例中有7个是低甲基化的,4个是高甲基化的。对8个相关基因的焦磷酸测序研究独立地证实了阵列上查询的CpG位点以及附近的其他CpG位点是差异甲基化的。为了验证这些发现,我们评估了10个RMS细胞系(5个融合阳性和5个融合阴性)的甲基化状态。非监督分析表明,这些细胞系根据融合状态聚集在一起,11个探针特征足以正确地分类这10个株系的融合状态。在另一组分析中,我们调查了这些RMS肿瘤中甲基化和基因表达之间的关系。在同时具有甲基化(人类甲基化27)和表达(U133 Plus 2.0)数据的RMS病例中,mRNA表达和启动子甲基化总体上呈负相关。然而,在145个同时存在差异启动子甲基化和差异表达的基因中,57%的基因甲基化与表达呈负相关,43%的基因甲基化与表达呈正相关。为了确定融合转录因子(PAX3-FOX01和PAX7-FOXO1)是否影响这些问题,我们分析了PAX3-FOXO1结合位点在这些差异甲基化基因中的分布。虽然PAX3-FOXO1结合位点在差异甲基化和非差异甲基化基因中的分布没有显著差异,但在差异甲基化也有差异表达的基因中,PAX3-FOXO1结合位点丰富。
英文摘要
The immediate goal of this project was to investigate differences in DNA methylation between fusion-positive and fusion-negative rhabdomyosarcoma (RMS) tumors. In preparation for this analysis, the Infinium HumanMethylation27 BeadChip database was edited to remove probes that localized to the X and Y chromosomes or repetitive regions, probes containing polymorphic sites, probes with ambiguous genomic locations or probes without detectable signal. Application of unsupervised analysis algorithms to this edited database demonstrated two distinct clusters, one containing the fusion-positive RMS cases and one containing the fusion-negative RMS cases. This differential methylation was further characterized by an increased incidence of hypomethylated sites in the fusion-positive compared to the fusion-negative tumors. Among probes that are differentially methylated between the two RMS subtypes, there were 3-fold more hypomethylated than hypermethylated sites in the fusion-positive subset. This differential methylation was particularly prominent in probes mapping to promoter regions and/or CpG islands. Since the initial analysis determined that methylation status was sufficient to classify the fusion status of an RMS tumor, we next investigated the number of probes that were needed for this classification. A training algorithm to find the minimum number of discriminating CpG sites determined that the methylation status of 11 probes is sufficient to classify the fusion-positive from the fusion-negative RMS tumors. In this group of 11 probes, seven were hypomethylated and four were hypermethylated in the fusion-positive compared to the fusion-negative cases. Pyrosequencing studies of eight of the associated genes independently confirmed that the CpG site queried on the array as well as other nearby CpG sites were differential methylated. To validate these findings, we assessed the methylation status in a collection of ten RMS cell lines (five fusion-positive and five fusion-negative). Unsupervised analysis revealed that these cell lines clustered according to fusion status and that the eleven probe signature was sufficient to correctly classify the fusion status in these 10 lines. In another set of analyses, we investigated the relationship between methylation and gene expression in these RMS tumors. In RMS cases with both methylation (HumanMethylation27) and expression (U133 Plus 2.0) data, there was an overall inverse relationship of mRNA expression and promoter methylation. However, among the 145 genes with both differential promoter methylation and differential expression, 57% showed an inverse correlation between methylation and expression whereas 43% showed a direct correlation. To determine whether the fusion transcription factors (PAX3-FOX01 and PAX7-FOXO1) impact on these issues, we analyzed the distribution of PAX3-FOXO1 binding sites among these differentially methylated genes. Though there was no significant difference in the distribution of PAX3-FOXO1 binding sites between genes with and without differential methylation, PAX3-FOXO1 binding sites are enriched among differentially methylated genes that are also differentially expressed.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Studies of gene fusions in rhabdomyosarcoma
  • 批准号:
    10486830
  • 项目类别:
  • 资助金额:
    $70.45万
  • 财政年份:
    --
  • 负责人:
    Frederic Barr
  • 依托单位:
Studies of amplification in rhabdomyosarcoma
Studies of amplification in rhabdomyosarcoma
Clinical Operations for Laboratory of Pathology
国内基金
海外基金
CRISPR/Cas9全基因组文库筛选Venetoclax/Azacitidine耐药关键基因及其机制研究